Receptor Biologix acquires Aphton's Insegia

Receptor Biologix (San Francisco, Calif.) acquired APHTQ's Insegia (G17DT) cancer vaccine in a Chapter 11 bankruptcy sale. Receptor Biologix said it expects to pay no more than $1 million for the prod...